Investors Purchase High Volume of Call Options on United Therapeutics (NASDAQ:UTHR)

United Therapeutics Corporation (NASDAQ:UTHR) was the recipient of unusually large options trading activity on Monday. Stock traders bought 16,791 call options on the company. This is an increase of approximately 789% compared to the average volume of 1,888 call options.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: TETON‑1 met its primary endpoint, showing a 130.1 mL superiority vs. placebo in absolute FVC change (Hodges‑Lehmann estimate; 95% CI 82.2 to 178.1), a clinically meaningful result in a 598‑patient trial — this is the direct catalyst for the stock rally. Business Wire: TETON-1 Press Release
• Positive Sentiment: Street response: TD Cowen raised its price target to $660 and kept a Buy rating, signaling analyst confidence in revenue upside from IPF expansion. Benzinga: TD Cowen Price Target Raise
• Neutral Sentiment: Peer/sector read‑through: Insmed shares rose after analysts viewed UTHR’s positive data as supportive for the broader interstitial lung disease/IPF space; a Morgan Stanley upgrade on Insmed underscores potential re‑rating across peers. Investing.com: Insmed Read-Through
• Negative Sentiment: Insider activity: CEO Martine Rothblatt sold 9,500 shares (disclosed March 26), which some investors may view as a modest negative signal or routine liquidity; monitor for additional insider moves. InsiderTrades: CEO Sale

United Therapeutics Trading Up 12.7%

UTHR stock traded up $66.64 during mid-day trading on Monday, hitting $589.47. 754,560 shares of the company were exchanged, compared to its average volume of 453,684. The company has a market capitalization of $25.84 billion, a PE ratio of 21.14, a price-to-earnings-growth ratio of 1.88 and a beta of 0.84. The firm has a fifty day simple moving average of $495.95 and a 200 day simple moving average of $473.67. United Therapeutics has a twelve month low of $266.98 and a twelve month high of $607.89.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping the consensus estimate of $6.78 by $0.92. The firm had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. United Therapeutics’s quarterly revenue was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $6.19 EPS. As a group, sell-side analysts anticipate that United Therapeutics will post 24.48 earnings per share for the current year.

Insider Buying and Selling at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $9,956,712.48. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $471.91, for a total value of $10,617,975.00. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 333,820 shares of company stock valued at $165,495,478. Corporate insiders own 10.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Geneos Wealth Management Inc. grew its position in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares in the last quarter. Creative Planning raised its holdings in shares of United Therapeutics by 10.1% in the 2nd quarter. Creative Planning now owns 4,270 shares of the biotechnology company’s stock worth $1,227,000 after buying an additional 392 shares in the last quarter. Advisors Asset Management Inc. boosted its position in United Therapeutics by 3.1% during the 2nd quarter. Advisors Asset Management Inc. now owns 4,013 shares of the biotechnology company’s stock worth $1,153,000 after buying an additional 121 shares during the period. Choreo LLC bought a new position in shares of United Therapeutics in the second quarter valued at approximately $220,000. Finally, Quadrant Capital Group LLC raised its stake in shares of United Therapeutics by 60.8% during the 2nd quarter. Quadrant Capital Group LLC now owns 4,722 shares of the biotechnology company’s stock worth $1,357,000 after purchasing an additional 1,786 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have commented on the company. HC Wainwright lifted their price target on United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Oppenheimer raised their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. UBS Group increased their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Finally, Wells Fargo & Company increased their price objective on shares of United Therapeutics from $466.00 to $486.00 and gave the stock an “equal weight” rating in a research report on Monday, March 23rd. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $557.64.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.